勃起功能障碍:治疗方法,进展和新的治疗策略
Antonio Argiolas1, Francesco Mario Argiolas1, Giacomo Argiolas2
1Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, Italy.
勃起功能障碍 (ED) 影响着数以百万计的男性,目前的治疗方法如口服药物和注射可以提供暂时的缓解. 再生疗法显示出对持久治疗的希望,但在可访问性和成本方面面临挑战.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 安德罗学与人类学
- 神经药理学神经药理学
- 再生医学是一种再生医学.
- 血管外科 血管外科
- 假肢手术 假肢手术
背景情况:
- 勃起功能障碍 (ED) 是一种常见的疾病,影响男性的生活质量,特别是随着年龄的增长.
- 现有的ED治疗方法包括口服药物和洞内注射,这些通常是按需的,并不总是有效的.
- 研究正在探索超越传统治疗的新疗法.
研究的目的:
- 审查目前和新兴的勃起功能障碍治疗策略.
- 突出现有治疗方法的局限性和新方法的潜力.
- 讨论与ED的先进再生治疗相关的挑战.
主要方法:
- 审查现有的关于治疗勃起功能障碍的文献.
- 对药理干预的分析,包括化酶5抑制剂和洞内药物.
- 探索关于新药点和再生疗法 (如干细胞和冲击波治疗) 的临床前发现.
主要成果:
- 目前对ED的药物治疗提供了症状缓解,但没有治愈作用.
- 像干细胞和体外冲击波治疗等再生疗法显示出组织修复的潜力,但复杂且昂贵.
- 对于难以治疗的ED,机械设备和阴茎假肢仍然是选择,尽管假肢的使用仅限于精心挑选的患者.
结论:
- 虽然新的再生疗法为长期ED解决方案提供了希望,但它们目前是劳动密集型,昂贵且难以复制的.
- 对于许多患者来说,传统治疗仍然是主要的支柱,侵袭性选择只适用于严重的,难以治疗的病例.
- 需要进一步的研究来开发可访问和有效的勃起功能障碍再生策略.
更多相关视频
03:51Author Spotlight: Advanced Treatment of Seminal Duct Blockage Employing Endoscopy-Mediated Semen Channel Refluviation
Published on: December 8, 2023
02:21Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Male Sexual Response: Erection & Ejaculation
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis III: Management
